Want to see VCEL full AI Analyst Report?
VCEL Stock Chart & Stats
$45.05
$0.27(0.60%)
At close: 4:00 PM EDT
$45.05
$0.27(0.60%)
Day’s Range― - ―
52-Week Range$28.95 - $49.32
Previous Close$45
Volume394.66K
Average Volume (3M)626.39K
Market Cap
$2.28B
Enterprise Value$2.26K
Total Cash (Recent Filing)$162.46M
Total Debt (Recent Filing)$92.54M
Price to Earnings (P/E)92.1
Beta0.84
Next Earnings
Nov 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding51,206,615
10 Day Avg. Volume486,320
30 Day Avg. Volume626,386
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$61.50Price Target Upside36.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.55
Revenue Forecast (FY)$335.88M
Bulls Say, Bears Say
Bulls Say
Margin Expansion & Sustained ProfitabilityVericel has moved from multi-year losses to sustainable profitability with materially expanded gross and net margins. Higher gross margins reflect scalable manufacturing and pricing power in autologous therapies, supporting durable cash flow and reinvestment capacity.
Strong Cash Generation And Improving Balance SheetConsistent operating cash flow and sizable TTM free cash flow indicate strong cash conversion of earnings. This durable cash generation reduces refinancing risk, funds growth investments (facility, trials, sales), and underpins the company’s ability to de-lever and return capital if sustained.
Leading MACI Franchise And Commercial ExecutionMACI’s persistent double-digit growth and improved biopsy-to-implant metrics reflect structural adoption gains and effective sales expansion. Durable surgeon adoption, scale manufacturing approval, and a clear international pathway strengthen the company’s core market position over coming years.
Bears Say
Dependence On Biopsy-to-implant ConversionRevenue growth for MACI hinges on maintaining biopsy-to-implant conversion rates across expanding territories. Conversion is operational and behavioral, sensitive to surgeon habits and payer access; a sustained drop would directly compress volumes and undermine long-term revenue momentum.
BARDA Revenue Timing & ContingencyWhile the BARDA award is strategically meaningful, much of its value is optional and multi-year. Reliance on contingent government procurement creates durable uncertainty in revenue forecasting and could lead to stepwise, lumpy contribution rather than steady, predictable top-line support.
Free-cash-flow Volatility And Reinvestment PressureAlthough TTM cash metrics are strong, historical free-cash-flow volatility and recent declines reflect working-capital swings and incremental investments (facility, trials, sales). Persistent volatility could pressure margins, constrain optionality, and complicate sustained deleveraging despite current cash balances.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $28.95 and its highest was $49.32 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $2.28B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on Jul 30, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.029 by $0.069.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is 0.06.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 51,206,615 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.029. Following the earnings report the stock price went up 2.124%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.50 (36.51% Upside)
$61.50 (36.51% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.44%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$61.50
▲(36.51% Upside)
Technical Analysis
Ownership Overview
1.19% Insiders
28.76% Mutual Funds
32.25% Other Institutional Investors
11.78% Public Companies and
Individual Investors